- Open
- 1.82
- High
- 1.83
- Low
- 1.76
- Close
- 1.82
- Change
- -0.05 (-2.78%)
- Volume
- 972,480
| 30 Oct 2026 | 07:00:02 | Total Voting Rights |
| 9 Oct 2026 | 13:39:16 | Corporate Update |
| 5 Oct 2026 | 07:00:07 | Presentation of Interim Results |
| 29 Sept 2026 | 13:46:11 | Exercise of Warrants and Issue of Equity |
| 29 Sept 2026 | 07:00:06 | Half-year Financial Report |
| 13 May 2026 | Annual financial statements 2025 | |
| 7 May 2025 | Annual financial statements 2024 | |
| 7 May 2024 | Audited Financial Statements Year Ended 2023 |
Genflow Biosciences plc develops gene therapies aimed at extending healthspan and addressing age-related conditions in both humans and canines. The company operates through two main divisions: Human Health, focusing on conditions such as metabolic dysfunction and sarcopenia, and Animal Health, which includes clinical trials for age-related issues in dogs. Genflow utilizes a proprietary SIRT6 gene therapy platform and has transitioned to LNP/mRNA delivery technologies to enhance treatment efficacy. The company is based in the United Kingdom and engages in research and development activities supported by grants and partnerships.
| 30 Oct 2026 | 07:00:02 | Total Voting Rights |
| 9 Oct 2026 | 13:39:16 | Corporate Update |
| 5 Oct 2026 | 07:00:07 | Presentation of Interim Results |
| 29 Sept 2026 | 13:46:11 | Exercise of Warrants and Issue of Equity |
| 29 Sept 2026 | 07:00:06 | Half-year Financial Report |
| 13 May 2026 | Annual financial statements 2025 | |
| 7 May 2025 | Annual financial statements 2024 | |
| 7 May 2024 | Audited Financial Statements Year Ended 2023 |
Genflow Biosciences plc develops gene therapies aimed at extending healthspan and addressing age-related conditions in both humans and canines. The company operates through two main divisions: Human Health, focusing on conditions such as metabolic dysfunction and sarcopenia, and Animal Health, which includes clinical trials for age-related issues in dogs. Genflow utilizes a proprietary SIRT6 gene therapy platform and has transitioned to LNP/mRNA delivery technologies to enhance treatment efficacy. The company is based in the United Kingdom and engages in research and development activities supported by grants and partnerships.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £103m | -0.1% | |
| £16m | -0.0% | |
GENFGenflow Biosciences plc | £11m | -0.1% |
| £10m | -0.0% | |
| £5m | -0.3% | |
| £2m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £103m | -0.1% | |
| £16m | -0.0% | |
GENFGenflow Biosciences plc | £11m | -0.1% |
| £10m | -0.0% | |
| £5m | -0.3% | |
| £2m | -0.7% |
